Congratulations to our client Neurocrine Biosciences for appointing Mike Sibley as SVP & General Manager Neuro-Psych Franchise.
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to discovering and developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio includes FDA-approved therapies for tardive dyskinesia, Huntington’s disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids, along with a robust pipeline of mid- to late-stage compounds. For more than 30 years, Neurocrine has advanced bold science to ease the burden of complex, debilitating conditions.
C1 Team: Christos Richards, Tom Murphy, Evan Fishel, James Reynolds & Leo Cain